Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Junwen Zhou, Aurélie Millier, Clément François, Samuel Aballéa & Mondher Toumi. (2019) Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results. Journal of Market Access & Health Policy 7:1.
Read now
Read now
Junwen Zhou, Aurélie Millier & Mondher Toumi. (2018) Systematic review of pharmacoeconomic models for schizophrenia. Journal of Market Access & Health Policy 6:1.
Read now
Read now
Kruti Joshi, Xiaoyun Pan, Rosa Wang, Erru Yang & Carmela Benson. (2016) Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate. Current Medical Research and Opinion 32:11, pages 1873-1881.
Read now
Read now
Thomas R. Einarson, Susana Maia-Lopes, Pushpendra Goswami, Basil G. Bereza & Kristel Van Impe. (2016) Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal. Journal of Medical Economics 19:9, pages 913-921.
Read now
Read now
Thomas R. Einarson, Hanna Pudas, Pushpendra Goswami, Kristel van Impe & Basil G. Bereza. (2016) Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland. Journal of Medical Economics 19:2, pages 121-130.
Read now
Read now
Articles from other publishers (7)
Huajie Jin, Paul Tappenden, Stewart Robinson, Evanthia Achilla, James H. MacCabe, David Aceituno & Sarah Byford. (2020) A Systematic Review of Economic Models Across the Entire Schizophrenia Pathway. PharmacoEconomics 38:6, pages 537-555.
Crossref
Crossref
Flore Decuypere, Jan Sermon, Paul Geerts, Tom R. Denee, Cedric De Vos, Bart Malfait, Mark Lamotte & Cornelis L. Mulder. (2017) Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study. PLOS ONE 12:6, pages e0179049.
Crossref
Crossref
L. Díaz-Castro, H. Cabello-Rangel, A. Arredondo, E. Madrigal de León & C. Pineda-Antúnez. (2017) Cost-effectiveness of therapeutic interventions in schizophrenia. The European Journal of Psychiatry 31:1, pages 11-16.
Crossref
Crossref
Mônica Kayo & Denise Razzouk. 2017. Mental Health Economics. Mental Health Economics
313
322
.
Sylvain Druais, Agathe Doutriaux, Magali Cognet, Annabelle Godet, Christophe Lançon, Pierre Levy, Ludovic Samalin & Pascal Guillon. (2016) Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France. PharmacoEconomics 34:4, pages 363-391.
Crossref
Crossref
Charlotte Deogan, Natalie Zarabi, Nils Stenstr?m, Pi H?gberg, Eva Sk?rstrand, Edison Manrique-Garcia, Kristian Neovius & Anna M?nsdotter. (2015) Cost-Effectiveness of School-Based Prevention of Cannabis Use. Applied Health Economics and Health Policy 13:5, pages 525-542.
Crossref
Crossref
Michael Sonntag, Hans-Helmut König & Alexander Konnopka. (2013) The Estimation of Utility Weights in Cost-Utility Analysis for Mental Disorders: A Systematic Review. PharmacoEconomics 31:12, pages 1131-1154.
Crossref
Crossref